Breaking News
Get 40% Off 0
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks
Close

Jiangxi Sanxin Medtec Co Ltd (300453)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
7.44 +0.11    +1.50%
26/04 - Closed. Currency in CNY ( Disclaimer )
Type:  Equity
Market:  China
ISIN:  CNE100001ZJ1 
  • Volume: 4,738,746
  • Bid/Ask: 7.44 / 7.44
  • Day's Range: 7.26 - 7.47
Jiangxi Sanxin Medtec Co Ltd 7.44 +0.11 +1.50%

Jiangxi Sanxin Medtec Co Ltd Company Profile

 
Get an in-depth profile of Jiangxi Sanxin Medtec Co Ltd, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryHealthcare Equipment & Supplies
SectorHealthcare
Employees

1879

Equity Type

ORD

Jiang Xi Sanxin Medtec Co., Ltd. is a China-based company principally engaged in research, development, manufacture and sales of disposable sterile injection medical devices. The Company's products include five series: syringe series, infusion & transfusion series, catheter tubing series, blood purification series and other series. The Company distributes its products within the domestic markets and to overseas markets.

Contact Information

Address No. 999 Fushan Road Xiaolan Economic Development Zone
Nanchang, 330200
China
Phone 86 79 1859 50275
Fax 86 79 1859 88819

Top Executives

Name Age Since Title
Zhiping Mao 47 - GM & Non-Independent Director
Fenglian Lei 60 - Vice Chairman
Yixing Peng 63 - Non-Independent Chairman
Haihong Jiang 43 - Independent Director
Zhenrong Le 62 2021 Deputy GM & Non-Independent Director
Lin Zhang 39 - Non-Employee Supervisor
Zhenzhu Yu 48 - Chairman of the Board of Supervisors
Guofeng Chen - 2023 Independent Director
Xiaohua Xia - 2023 Independent Director
Meihua Zeng 36 2020 Supervisor
Ming Liu 33 2019 VP, Board Secretary & Non-Independent Director
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

300453 Comments

Write your thoughts about Jiangxi Sanxin Medtec Co Ltd
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email